AstraZeneca Establishes Cell Therapy Manufacturing and Innovation Centre in Shanghai

jueves, 19 de marzo de 2026, 12:56 am ET1 min de lectura
AZN--

AstraZeneca plans to build a cell therapy manufacturing and innovation center in Shanghai, aiming to be the first global drugmaker with end-to-end cell therapy capabilities in China. The facility will produce and supply autologous CAR-T cell therapies for China and other Asian markets.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios